Liver Cancer!
Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of six to nine months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.
Who Can Participate:
- 18 years of age or older
- Diagnosed with advanced HCC
- Not pregnant or breastfeeding
Study Design:
- Physical exam and medical history
- Imaging, such as CT or MRI scan
- Electrocardiogram (EKG)
- Patients will receive the study medications every two to four weeks
Location: The NIH Clinical Center, America's Research Hospital is located on the Metro red line (Medical Center stop) in Bethesda, MD.
For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
(TTY users dial 7-1-1)
Se habla español
Email: ccopr@nih.gov
Or go online:
https://go.usa.gov/xpeBG
Refer to study # 19-C-0094
Department of Health and Human Services
National Institutes of Health Clinical Center
National Cancer Institute